Zenotech Laboratories

Zenotech Laboratories EBITDA Margin

The EBITDA Margin of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -4.80 %. In the previous year, EBITDA Margin was 37.41 % — a change of -112.82% (lower).

EBITDA Margin

-4.80 %

YoY

-112.82%

Last updated:

EBITDA Margin of Zenotech Laboratories is 2026 -4.80 % . EBITDA Margin of Zenotech Laboratories was 2025 37.41 % . It decreases by -112.82% lower compared to the previous year.

The Zenotech Laboratories EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2019
-25.02 INR
Jan 1, 2020
59.18 INR
Jan 1, 2021
32.93 INR
Jan 1, 2022
49.20 INR
Jan 1, 2023
51.36 INR
Jan 1, 2024
42.28 INR
Jan 1, 2025
37.41 INR
Jan 1, 2026
-4.80 INR
The Zenotech Laboratories EBITDA Margin history
YEAREBITDA MarginYoY
-4.80 %-112.82%
37.41 %-11.53%
42.28 %-17.66%
51.36 %+4.37%
49.20 %+49.41%
32.93 %-44.35%
59.18 %-336.56%
-25.02 %-64.33%
-70.14 %-81.48%
-378.67 %+7.94%
-350.80 %+51.25%
-231.93 %-66.19%
-685.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

EBITDA Margin of Zenotech Laboratories is -4.80 % in 2026.

EBITDA Margin of Zenotech Laboratories changed from 37.41 % to -4.80 %, representing a -112.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories